The SITC Forward Fund is pleased to announce the recipients of the 2024 SITC Fellowships, supporting the next generation of cancer immunotherapy and tumor immunology experts, providing dedicated funding of impactful research.
The fellowship recipients were honored during a ceremony at the society’s 39th Annual Meeting.
The 2024 SITC Forward Fund Fellowship recipients are:
SITC-Bristol Myers Squibb Postdoctoral Cancer Immunotherapy Translational Fellowship
Award Amount: $200,000 (two-year)
Recipient: Elisa Bergaggio, PhD
Institution: Boston Children’s Hospital
Project Title: “Enhancing ALK.CAR-T efficacy in solid tumors”
SITC-MRA Women in Melanoma Fellowship
Award Amount: $200,000 (two-year)
Recipient: Arielle Elkrief, MD
Institution: University of Montreal
Project Title: “Identification of the next generation of microbiome therapeutics in combination with immune checkpoint blockade to improve outcomes for patients with melanoma”
SITC-Merck Cancer Immunotherapy Clinical Fellowship
Award Amount: $100,000 (one-year)
Awardee: Benjamin R. Schrank, MD, PhD
Institution: The University of Texas MD Anderson Cancer Center
Project Title: “Enhancing Tumor-Immune Interactions in Breast Cancer via an Immunostimulatory Antibody-Drug Conjugate
SITC Diversity, Equity and Inclusion Fellowship
Award Amount: $100,000 (one-year)
Awardee: Victor Arrieta, MD, PhD
Institution: Northwestern University
Project Title: “Leveraging DNA Methylation Signatures to Decode Clinical Responses to Immune Checkpoint Blockade in Glioblastoma”
SITC-Mallinckrodt Pharmaceuticals Adverse Events in Cancer Immunotherapy Clinical Fellowship
Award Amount: $40,000 (one-year)
Recipient: Gabriele Casirati, MD, PhD
Institution: Dana-Farber Cancer Institute
Project Title: “Epitope edited Hematopoietic Stem Cells to Eliminate On-target/Off-tumor Toxicity”
2024 NCI Immunotherapy Fellowship
Award: This one-year program allows the fellow to have exposure to multiple clinical immunotherapeutic approaches and also to key opinion leaders in the field of clinical immunotherapy.
Co-sponsored by the National Cancer Institute (NCI) and SITC, made possible in part by an educational grant from EMD Serono.
Awardee: Matthew Rosenthal, MD
Institution: The George Washington University
This year’s SITC Forward Fund Fellowships were made possible through the generosity of Bristol Myers Squibb, Mallinckrodt Pharmaceuticals and Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. and Melanoma Research Alliance.